Brain mitochondrial complex I inactivation by oxidative modification

被引:31
作者
Bautista, J [1 ]
Corpas, R
Ramos, R
Cremades, O
Gutiérrez, JF
Alegre, S
机构
[1] Univ Sevilla, Fac Farm, Dept Bioquim Bromatol & Toxicol, E-41012 Seville, Spain
[2] Hosp San Juan Dios, Seville 41002, Spain
关键词
complex I; Parkinson's disease; protein oxidation; non-synaptosoma mitochondia;
D O I
10.1006/bbrc.2000.3388
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vitro oxidation of the brain mitochondrial complex I by the hydroxyl radical generating system ascorbate/Fe(III)/O-2 has been carried out. Complex I inactivation, by oxidation, has been studied using a method based on the resolution of proteins by blue native polyacrylamide gel electrophoresis (BN-PAGE), followed by total protein quantification by staining with Coomassie brilliant blue, in-gel activity quantification, and quantification of oxidized proteins by labelling with DIG-hydrazide and immunodetection with an anti-DIG-AP. Quantification was carried out by densitometry procedure. Our results show that oxidation is a continuous process, increasing rapidly at the beginning, reaching a plateau after 8 h of incubation. There is practically no inactivation until a threshold value of damage is reached. Below this, the complex activity is resistant to the aggression of oxygen-reactive substances and free radicals, but once the threshold value is passed, activity is lost rapidly. (C) 2000 Academic Press.
引用
收藏
页码:890 / 894
页数:5
相关论文
共 40 条
  • [11] Reactive oxygen species: the unavoidable environmental insult?
    Gracy, RW
    Talent, JM
    Kong, Y
    Conrad, CC
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1999, 428 (1-2) : 17 - 22
  • [12] LOW PLATELET MITOCHONDRIAL COMPLEX-I AND COMPLEX-II/III ACTIVITY IN EARLY UNTREATED PARKINSONS-DISEASE
    HAAS, RH
    NASIRIAN, F
    NAKANO, K
    WARD, D
    PAY, M
    HILL, R
    SHULTS, CW
    [J]. ANNALS OF NEUROLOGY, 1995, 37 (06) : 714 - 722
  • [13] UNALTERED ACONITASE ACTIVITY, BUT DECREASED COMPLEX-I ACTIVITY IN SUBSTANTIA-NIGRA PARS-COMPACTA OF PATIENTS WITH PARKINSONS-DISEASE
    JANETZKY, B
    HAUCK, S
    YOUDIM, MBH
    RIEDERER, P
    JELLINGER, K
    PANTUCEK, F
    ZOCHLING, R
    BOISSL, KW
    REICHMANN, H
    [J]. NEUROSCIENCE LETTERS, 1994, 169 (1-2) : 126 - 128
  • [14] JENNER P, 1994, LANCET, V344, P797
  • [15] Parkinson's disease and free radicals - Mechanism of neurodegeneration and neuroprotection
    Kondo, T
    [J]. PHARMACOLOGICAL INTERVENTION IN AGING AND AGE-ASSOCIATED DISORDERS: PROCEEDINGS OF THE SIXTH CONGRESS OF THE INTERNATIONAL ASSOCIATION OF BIOMEDICAL GERONTOLOGY, 1996, 786 : 206 - 216
  • [16] KRIEGE D, 1992, ANN NEUROL, V32, P782
  • [17] Lai J.C.K., 1989, NeuroMethods, P43
  • [18] CHRONIC PARKINSONISM IN HUMANS DUE TO A PRODUCT OF MEPERIDINE-ANALOG SYNTHESIS
    LANGSTON, JW
    BALLARD, P
    TETRUD, JW
    IRWIN, I
    [J]. SCIENCE, 1983, 219 (4587) : 979 - 980
  • [19] DETERMINATION OF CARBONYL GROUPS IN OXIDATIVELY MODIFIED PROTEINS BY REDUCTION WITH TRITIATED SODIUM-BOROHYDRIDE
    LENZ, AG
    COSTABEL, U
    SHALTIEL, S
    LEVINE, RL
    [J]. ANALYTICAL BIOCHEMISTRY, 1989, 177 (02) : 419 - 425
  • [20] BRAIN, SKELETAL-MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE
    MANN, VM
    COOPER, JM
    KRIGE, D
    DANIEL, SE
    SCHAPIRA, AHV
    MARSDEN, CD
    [J]. BRAIN, 1992, 115 : 333 - 342